title: Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
abstract: OBJECTIVE
  To analyze the risk of developing myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) following autologous bone marrow transplantation (ABMT) or peripheral stem-cell transplantation (PSCT) and to determine the impact on failure-free survival (FFS).
  
  
  METHODS
  Patients underwent ABMT or PSCT for the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) at the University of Nebraska Medical Center. For those patients who went on to develop MDS/AML, controls were selected and a case-control-within-a-cohort study undertaken.
  
  
  RESULTS
  Twelve patients developed MDS or AML a median of 44 months following ABMT/PSCT. The cumulative incidence (P = .42) and the conditional probability (P = .32) of MDS/AML were not statistically different between HD and NHL patients. Age greater than 40 years at the time of transplant (P = .05) and receipt of a total-body irradiation (TBI)-containing regimen (P = .06) were predictive for developing MDS/AML in patients with NHL.
  
  
  CONCLUSIONS
  There is an increased risk of MDS/AML following ABMT/PSCT for lymphoid malignancies. NHL patients age > or = 40 years at the time of transplant and who received TBI are at greatest risk.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330.
authors.forename: D L
authors.initials: DL
authors.lastname: Darrington
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: J R
authors.initials: JR
authors.lastname: Anderson
authors.forename: P J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: W C
authors.initials: WC
authors.lastname: Chan
authors.forename: M E
authors.initials: ME
authors.lastname: Morris
authors.forename: E C
authors.initials: EC
authors.lastname: Reed
authors.forename: W G
authors.initials: WG
authors.lastname: Sanger
authors.forename: S R
authors.initials: SR
authors.lastname: Tarantolo
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D016022:Case-Control Studies; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006689:Hodgkin Disease / Q000401:mortality / Q000628:therapy*; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000209:etiology*; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000453:epidemiology / Q000209:etiology*; D011379:Prognosis; D011879:Radiotherapy Dosage; D012307:Risk Factors; D015996:Survival Rate; D014916:Whole-Body Irradiation